These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29611211)

  • 21. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimax and admissible adaptive two-stage designs in phase II clinical trials.
    Shan G; Zhang H; Jiang T
    BMC Med Res Methodol; 2016 Aug; 16():90. PubMed ID: 27485595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimal seamless phase 2/3 oncology trial designs based on Probability of Success (PoS).
    Teng Z; Liang L; Liu G; Liu Y
    Stat Med; 2018 Dec; 37(28):4097-4113. PubMed ID: 30084110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuous and group sequential conditional probability ratio tests for phase II clinical trials.
    Tan M; Xiong X
    Stat Med; 1996 Oct; 15(19):2037-51. PubMed ID: 8896138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design of Phase II cancer trials evaluating survival probabilities.
    Case LD; Morgan TM
    BMC Med Res Methodol; 2003 Apr; 3():6. PubMed ID: 12697051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exact two-stage designs for phase II activity trials with rank-based endpoints.
    Wilding GE; Shan G; Hutson AD
    Contemp Clin Trials; 2012 Mar; 33(2):332-41. PubMed ID: 22074983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adaptive designs for single-arm phase II trials in oncology.
    Englert S; Kieser M
    Pharm Stat; 2012; 11(3):241-9. PubMed ID: 22411839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stochastic curtailment tests for phase II trial with time-to-event outcome using the concept of relative time in the case of non-proportional hazards.
    Sharma P; Phadnis MA
    J Biopharm Stat; 2024 Jul; 34(4):596-611. PubMed ID: 37574976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantifying the bias in the estimated treatment effect in randomized trials having interim analyses and a rule for early stopping for futility.
    Walter SD; Han H; Briel M; Guyatt GH
    Stat Med; 2017 Apr; 36(9):1506-1518. PubMed ID: 28183155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal flexible designs in phase II clinical trials.
    Chen TT; Ng TH
    Stat Med; 1998 Oct; 17(20):2301-12. PubMed ID: 9819829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized phase II designs in cancer clinical trials: current status and future directions.
    Lee JJ; Feng L
    J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal two-stage designs for single-arm phase II oncology trials with two binary endpoints.
    Kunz CU; Kieser M
    Methods Inf Med; 2011; 50(4):372-7. PubMed ID: 21057719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unified exact design with early stopping rules for single arm clinical trials with multiple endpoints.
    Wei W; Esserman D; Kane M; Zelterman D
    Stat Methods Med Res; 2021 Jul; 30(7):1575-1588. PubMed ID: 34159859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Bayesian predictive two-stage design for phase II clinical trials.
    Sambucini V
    Stat Med; 2008 Apr; 27(8):1199-224. PubMed ID: 17763528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A systematic survey of randomised trials that stopped early for reasons of futility.
    Walter SD; Han H; Guyatt GH; Bassler D; Bhatnagar N; Gloy V; Schandelmaier S; Briel M
    BMC Med Res Methodol; 2020 Jan; 20(1):10. PubMed ID: 31948397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.
    Taylor DJ; Grobler A; Abdool Karim SS
    Clin Trials; 2012 Aug; 9(4):377-84. PubMed ID: 22610168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimality criteria for futility stopping boundaries for group sequential designs with a continuous endpoint.
    Li X; Herrmann C; Rauch G
    BMC Med Res Methodol; 2020 Nov; 20(1):274. PubMed ID: 33153438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of a new multinomial phase II stopping rule using response and early progression.
    Dent S; Zee B; Dancey J; Hanauske A; Wanders J; Eisenhauer E
    J Clin Oncol; 2001 Feb; 19(3):785-91. PubMed ID: 11157032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints.
    Zhou H; Lee JJ; Yuan Y
    Stat Med; 2017 Sep; 36(21):3302-3314. PubMed ID: 28589563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of Bayesian predictive probability for interim futility analysis in single-arm phase II trial.
    Chen DT; Schell MJ; Fulp WJ; Pettersson F; Kim S; Gray JE; Haura EB
    Transl Cancer Res; 2019 Jul; 8(Suppl 4):S404-S420. PubMed ID: 31456910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.